Ratings by Cantor Fitzgerald (Olivia Brayer)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/25/2026 | Quince Therapeutics Inc. | QNCX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/24/2026 | Tenax Therapeutics | TENX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/23/2026 | Quince Therapeutics Inc. | QNCX | New Coverage | Overweight (N/A) |
0.93 (17.25) |
1754.84% | Details | |
| 6/10/2026 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/19/2026 | Inhibikase Therapeutics Inc | IKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/1/2026 | Pelthos Therapeutics | PTHS | New Coverage | Overweight (N/A) |
21.01 (26.25) |
24.94% | Details | |
| 3/23/2026 | Gossamer Bio Inc. | GOSS | Downgrade | Neutral (Overweight) |
0.45 (0.14) |
-68.89% | Details | |
| 3/12/2026 | United Therapeutics Corp. | UTHR | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/2/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/4/2026 | CytomX Therapeutics | CTMX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/22/2026 | Gossamer Bio Inc. | GOSS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/16/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (Neutral) |
|
Details | ||
| 12/18/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/17/2025 | Vanda Pharmaceuticals | VNDA | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/11/2025 | Inhibikase Therapeutics Inc | IKT | New Coverage | Overweight (N/A) |
1.48 (1.96) |
32.43% | Details | |
| 11/20/2025 | CytomX Therapeutics | CTMX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/13/2025 | Gossamer Bio Inc. | GOSS | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | Vanda Pharmaceuticals | VNDA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | Vanda Pharmaceuticals | VNDA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/28/2025 | Insmed | INSM | New Coverage | Overweight (N/A) |
164.02 (109.14) |
-33.46% | Details | |
| 10/22/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (Neutral) |
|
Details | ||
| 10/14/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/22/2025 | CytomX Therapeutics | CTMX | New Coverage | Overweight (N/A) |
1.98 (3.70) |
86.87% | Details | |
| 9/10/2025 | United Therapeutics Corp. | UTHR | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/14/2025 | United Therapeutics Corp. | UTHR | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/5/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/17/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/11/2025 | Verona Pharma | VRNA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2025 | United Therapeutics Corp. | UTHR | New Coverage | Overweight (N/A) |
318.85 (535.57) |
67.97% | Details | |
| 5/14/2025 | Vanda Pharmaceuticals | VNDA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/2/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/21/2025 | Verona Pharma | VRNA | New Coverage | Overweight (N/A) |
58.92 (106.91) |
81.45% | Details | |
| 3/21/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/20/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/11/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2025 | Amgen | AMGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/4/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/31/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/24/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/12/2024 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2024 | Amgen | AMGN | New Coverage | Overweight (N/A) |
319.10 (360.45) |
12.96% | Details | |
| 7/26/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2024 | Aurinia Pharmaceuticals | AUPH | Maintain | Overweight (N/A) |
|
Details | ||
| 1/24/2024 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2023 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (Overweight) |
50.52 (48.94) |
-3.13% | Details | |
| 11/2/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2023 | CRISPR Therapeutics | CRSP | Downgrade | Neutral (Buy) |
44.81 (50.63) |
12.99% | Details | |
| 8/2/2023 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/5/2023 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/13/2023 | CRISPR Therapeutics | CRSP | New Coverage | Overweight (N/A) |
43.47 (50.63) |
16.47% | Details | |
| 2/23/2023 | Graphite Bio Inc | GRPH | Downgrade | Neutral (Overweight) |
2.20 (3.18) |
44.55% | Details | |
| 1/17/2023 | Bristol-Myers Squibb Co. | BMY | New Coverage | Overweight (N/A) |
72.51 (59.34) |
-18.16% | Details | |
| 1/6/2023 | Graphite Bio Inc | GRPH | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2022 | Graphite Bio Inc | GRPH | New Coverage | Overweight (N/A) |
3.61 (3.18) |
-11.91% | Details | |
| 7/13/2022 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
87.83 (59.20) |
-32.6% | Details | |
| 7/13/2022 | Vertex | VRTX | New Coverage | Overweight (N/A) |
294.07 (480.25) |
63.31% | Details | |
| 7/13/2022 | Regeneron Pharma | REGN | New Coverage | Neutral (N/A) |
614.46 (663.09) |
7.91% | Details | |
| 7/13/2022 | Gilead Sciences | GILD | New Coverage | Neutral (N/A) |
62.66 (131.40) |
109.7% | Details | |
| 7/13/2022 | Alnylam Pharmaceuticals | ALNY | New Coverage | Neutral (N/A) |
150.91 (288.06) |
90.88% | Details | |
| 5/5/2022 | Aurinia Pharmaceuticals | AUPH | New Coverage | Overweight (N/A) |
11.37 (16.03) |
40.99% | Details |
